The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gastrointestinal Disorder Therapeutics Market Research Report 2025
Synopsis
Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food. Gastrointestinal disorders includes irritable bowel syndrome, gastroesophageal reflux diseases and peptic ulcer diseases.
The global Gastrointestinal Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Disorder Therapeutics.
Report Scope
The Gastrointestinal Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastrointestinal Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Takeda Pharmaceutical
Johnson & Johnson
Eisai
Abbott Laboratories
Salix Pharmaceuticals
Bausch Health
Allergan
Bayer
UCB
AbbVie
GlaxoSmithKline
Astellas Pharma
Segment by Type
Irritable Bowel Syndrome (IBS)
Chronic Constipation (CC)
Ulcerative Colitis (UC)
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Gastrointestinal disorder is mainly associated with the impairment of gastrointestinal functions that are affected mainly by contaminated or poisonous food. Gastrointestinal disorders includes irritable bowel syndrome, gastroesophageal reflux diseases and peptic ulcer diseases.
The global Gastrointestinal Disorder Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Disorder Therapeutics.
Report Scope
The Gastrointestinal Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gastrointestinal Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Takeda Pharmaceutical
Johnson & Johnson
Eisai
Abbott Laboratories
Salix Pharmaceuticals
Bausch Health
Allergan
Bayer
UCB
AbbVie
GlaxoSmithKline
Astellas Pharma
Segment by Type
Irritable Bowel Syndrome (IBS)
Chronic Constipation (CC)
Ulcerative Colitis (UC)
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastrointestinal Disorder Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Irritable Bowel Syndrome (IBS)
1.2.3 Chronic Constipation (CC)
1.2.4 Ulcerative Colitis (UC)
1.3 Market by Application
1.3.1 Global Gastrointestinal Disorder Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastrointestinal Disorder Therapeutics Market Perspective (2019-2030)
2.2 Gastrointestinal Disorder Therapeutics Growth Trends by Region
2.2.1 Global Gastrointestinal Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gastrointestinal Disorder Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Gastrointestinal Disorder Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Gastrointestinal Disorder Therapeutics Market Dynamics
2.3.1 Gastrointestinal Disorder Therapeutics Industry Trends
2.3.2 Gastrointestinal Disorder Therapeutics Market Drivers
2.3.3 Gastrointestinal Disorder Therapeutics Market Challenges
2.3.4 Gastrointestinal Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastrointestinal Disorder Therapeutics Players by Revenue
3.1.1 Global Top Gastrointestinal Disorder Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Gastrointestinal Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gastrointestinal Disorder Therapeutics Revenue
3.4 Global Gastrointestinal Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Gastrointestinal Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Disorder Therapeutics Revenue in 2023
3.5 Gastrointestinal Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Gastrointestinal Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Gastrointestinal Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastrointestinal Disorder Therapeutics Breakdown Data by Type
4.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Type (2025-2030)
5 Gastrointestinal Disorder Therapeutics Breakdown Data by Application
5.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gastrointestinal Disorder Therapeutics Market Size (2019-2030)
6.2 North America Gastrointestinal Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gastrointestinal Disorder Therapeutics Market Size by Country (2019-2024)
6.4 North America Gastrointestinal Disorder Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastrointestinal Disorder Therapeutics Market Size (2019-2030)
7.2 Europe Gastrointestinal Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gastrointestinal Disorder Therapeutics Market Size by Country (2019-2024)
7.4 Europe Gastrointestinal Disorder Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Disorder Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Gastrointestinal Disorder Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gastrointestinal Disorder Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Gastrointestinal Disorder Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastrointestinal Disorder Therapeutics Market Size (2019-2030)
9.2 Latin America Gastrointestinal Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gastrointestinal Disorder Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Gastrointestinal Disorder Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Disorder Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Gastrointestinal Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gastrointestinal Disorder Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Gastrointestinal Disorder Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Gastrointestinal Disorder Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Takeda Pharmaceutical
11.2.1 Takeda Pharmaceutical Company Detail
11.2.2 Takeda Pharmaceutical Business Overview
11.2.3 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Introduction
11.2.4 Takeda Pharmaceutical Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.2.5 Takeda Pharmaceutical Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Gastrointestinal Disorder Therapeutics Introduction
11.3.4 Johnson & Johnson Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 Eisai
11.4.1 Eisai Company Detail
11.4.2 Eisai Business Overview
11.4.3 Eisai Gastrointestinal Disorder Therapeutics Introduction
11.4.4 Eisai Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.4.5 Eisai Recent Development
11.5 Abbott Laboratories
11.5.1 Abbott Laboratories Company Detail
11.5.2 Abbott Laboratories Business Overview
11.5.3 Abbott Laboratories Gastrointestinal Disorder Therapeutics Introduction
11.5.4 Abbott Laboratories Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.5.5 Abbott Laboratories Recent Development
11.6 Salix Pharmaceuticals
11.6.1 Salix Pharmaceuticals Company Detail
11.6.2 Salix Pharmaceuticals Business Overview
11.6.3 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Introduction
11.6.4 Salix Pharmaceuticals Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.6.5 Salix Pharmaceuticals Recent Development
11.7 Bausch Health
11.7.1 Bausch Health Company Detail
11.7.2 Bausch Health Business Overview
11.7.3 Bausch Health Gastrointestinal Disorder Therapeutics Introduction
11.7.4 Bausch Health Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.7.5 Bausch Health Recent Development
11.8 Allergan
11.8.1 Allergan Company Detail
11.8.2 Allergan Business Overview
11.8.3 Allergan Gastrointestinal Disorder Therapeutics Introduction
11.8.4 Allergan Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.8.5 Allergan Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Gastrointestinal Disorder Therapeutics Introduction
11.9.4 Bayer Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.9.5 Bayer Recent Development
11.10 UCB
11.10.1 UCB Company Detail
11.10.2 UCB Business Overview
11.10.3 UCB Gastrointestinal Disorder Therapeutics Introduction
11.10.4 UCB Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.10.5 UCB Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Gastrointestinal Disorder Therapeutics Introduction
11.11.4 AbbVie Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.11.5 AbbVie Recent Development
11.12 GlaxoSmithKline
11.12.1 GlaxoSmithKline Company Detail
11.12.2 GlaxoSmithKline Business Overview
11.12.3 GlaxoSmithKline Gastrointestinal Disorder Therapeutics Introduction
11.12.4 GlaxoSmithKline Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.12.5 GlaxoSmithKline Recent Development
11.13 Astellas Pharma
11.13.1 Astellas Pharma Company Detail
11.13.2 Astellas Pharma Business Overview
11.13.3 Astellas Pharma Gastrointestinal Disorder Therapeutics Introduction
11.13.4 Astellas Pharma Revenue in Gastrointestinal Disorder Therapeutics Business (2019-2024)
11.13.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
